Financing

[Market Insight] Han Shin Rating Downgrades Credit Ratings of Four Central Group Affiliates… “Risk of Liquidity Contagion on the Rise”

SLL JoongAng, JoongAng Ilbo, Contentre JoongAng, and Megabox JoongAng All Down Listed Despite Downgrade Review…Excessive Financial Burden and Growing Liquidity Risks High Financial Interdependence Across the Group Heightens Uncertainty Regarding Borrowing Maturity Management

LEE GEON-EOM
2026-06-13 08:53:01
[Edaily Marketin, Reporter Lee Geon-eom] On the 13th, Korea Ratings (hereinafter "Korea Ratings") downgraded the credit ratings of four affiliates of the Joongang Group in a special review and placed them on "downgrade watch."
Exterior view of the JoongAng Ilbo headquarters in Sangam-dong. (Photo = JoongAng Ilbo)

The four companies subject to this adjustment are SSL JoongAng Co., Ltd., JoongAng Ilbo Co., Ltd., Contentre JoongAng Co., Ltd., and Megabox JoongAng Co., Ltd. Specifically, the credit ratings for unsecured corporate bonds of SSL JoongAng and JoongAng Ilbo were downgraded to ‘BB’. The credit ratings for commercial paper and short-term bonds of SSL JoongAng, Contentre JoongAng, and Megabox JoongAng were lowered to ‘B’.

Han Shin Rating cited the excessive financial burden across the entire affiliate group and the expansion of liquidity risks as the key reasons for this downgrade. The assessment is that, as the JoongAng Group has formed a structure with very high financial interdependence through intercompany loans and credit facilities among major affiliates, the possibility of a liquidity crisis at some affiliates spreading to the entire group is becoming a reality.

Kwon Hyuk-min, a senior analyst at Han Shin Rating responsible for evaluating SSL Joongang, JoongAng Ilbo, and Contentre Joongang, stated, “The group’s overall access to capital markets has weakened due to a short-term debt maturity structure and an excessive debt burden relative to cash flow,” adding, “We also assess that efforts to raise funds using held assets are being delayed, and uncertainty regarding the management of maturing debt—including securitized securities issued by affiliates—has increased.”

Hanshin Rating also views the risk of contagion within the group as high. Senior Analyst Kwon assessed, “Given the high level of financial interdependence across the group, the potential for liquidity risk to spread among affiliates appears to have increased.” In the same vein, Chae Seon-young, a senior analyst at Hanshin Rating responsible for the evaluation of Megabox Joongang, also stated, “We judge that uncertainty regarding the management of debt maturities has increased.”

Han Shin Rating plans to closely monitor the group’s future handling of maturing debt and its ability to raise funds through asset securitization. Observers note that any further credit rating adjustments will depend on how the company manages this liquidity crisis.

Meanwhile, NICE Credit Rating downgraded JTBC’s unsecured bond credit rating from ‘BBB (Negative)’ to ‘CCC’ the previous day. It also lowered the ratings for commercial paper (CP) and electronic short-term bonds from ‘A3’ to ‘C.’ A ‘CCC’ rating indicates a speculative grade, implying a low certainty of principal and interest repayment and containing speculative elements. #Korea Ratings also downgraded JTBC’s credit rating to ‘BB’. It also lowered the credit ratings of JoongAng Ilbo and SLL JoongAng to ‘BB+’.

Economy

Corporation

IT·Science

Economy

NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year

#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
2026-08-19 10:02:44

Corporation

Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs

Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
2026-08-19 09:54:02

IT·Science

LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology

# LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
2026-08-19 10:20:03